Czuchlewski David R, Foucar Kathryn
Department of Pathology, University of New Mexico, Albuquerque, NM 87131, USA.
Department of Pathology, University of New Mexico, Albuquerque, NM 87131, USA.
Surg Pathol Clin. 2013 Dec;6(4):661-76. doi: 10.1016/j.path.2013.08.002. Epub 2013 Oct 21.
Discrete diagnostic subtypes of T lymphoblastic leukemia/lymphoma (T-cell acute lymphoblastic leukemia/lymphoma, T-ALL) have historically not been widely recognized. Recently, a novel subset with distinctive immunophenotypic, molecular, and clinical features has been proposed. Termed early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), these cases seem to correspond to a very early stage of T-cell development. ETP-ALL is associated with a poor prognosis using standard protocols, and patients with ETP-ALL may benefit from intensified, alternative, or targeted therapies. Recognizing ETP-ALL and distinguishing it from other forms of acute leukemia are important elements of an up-to-date diagnostic approach to precursor T-cell neoplasms.
历史上,T淋巴细胞白血病/淋巴瘤(T细胞急性淋巴细胞白血病/淋巴瘤,T-ALL)的离散诊断亚型并未得到广泛认可。最近,一种具有独特免疫表型、分子和临床特征的新亚型被提出。这些病例被称为早期T细胞前体急性淋巴细胞白血病(ETP-ALL),似乎对应于T细胞发育的一个非常早期阶段。使用标准方案时,ETP-ALL的预后较差,ETP-ALL患者可能从强化、替代或靶向治疗中获益。识别ETP-ALL并将其与其他形式的急性白血病区分开来,是当前前体T细胞肿瘤诊断方法的重要组成部分。